13G Filing: Brookside Capital and Immune Design Corp. (IMDZ)

Page 3 of 7 – SEC Filing

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.07%

12.

TYPE OF REPORTING PERSON (see instructions)

PNCUSIP No. 45252L103

13G

Page 4 of 8 Pages1.

NAMES OF REPORTING PERSONS

Brookside Capital Trading Fund, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ?
(b) ?

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

DelawareNUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

1,299,013

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

1,299,013

8.

SHARED DISPOSITIVE POWER

09.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,299,013

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ?11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.07%

12.

TYPE OF REPORTING PERSON (see instructions)

PNCUSIP No. 45252L103

13G

Page 5 of 8Item 1.

(a)
Name of Issuer
The name of the issuer to which this filing on Schedule 13G
relates is Immune Design Corp. (the “Company”)

Follow Immune Design Corp. (NASDAQ:IMDZ)